Arkadios Wealth Advisors Makes New $1.82 Million Investment in Tyra Biosciences, Inc. $TYRA

Key Points

• Arkadios Wealth Advisors purchased 47,567 Tyra Biosciences shares worth approximately $1.82 million, while institutional investors and hedge funds collectively own 84.14% of the company.
• Tyra Biosciences reported a quarterly loss of $0.64 per share, missing the $0.60 consensus estimate; analysts expect a full-year loss of $2.68 per share.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $47, compared with the stock’s opening price of $31.88.

Arkadios Wealth Advisors purchased a new position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 47,567 shares of the company's stock, valued at approximately $1,822,000. Arkadios Wealth Advisors owned approximately 0.08% of Tyra Biosciences as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Commodore Capital LP grew its holdings in shares of Tyra Biosciences by 226.3% in the 2nd quarter. Commodore Capital LP now owns 3,100,000 shares of the company's stock valued at $29,667,000 after acquiring an additional 2,150,000 shares in the last quarter. Janus Henderson Group PLC raised its holdings in Tyra Biosciences by 2.1% during the fourth quarter. Janus Henderson Group PLC now owns 2,935,442 shares of the company's stock worth $77,085,000 after acquiring an additional 60,638 shares in the last quarter. Farallon Capital Management LLC boosted its position in Tyra Biosciences by 80.7% during the fourth quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company's stock valued at $54,337,000 after purchasing an additional 923,000 shares during the last quarter. Vanguard Group Inc. boosted its position in Tyra Biosciences by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,520,185 shares of the company's stock valued at $21,267,000 after purchasing an additional 118,492 shares during the last quarter. Finally, 5AM Venture Management LLC grew its stake in Tyra Biosciences by 9.6% in the fourth quarter. 5AM Venture Management LLC now owns 1,029,298 shares of the company's stock valued at $27,060,000 after purchasing an additional 90,000 shares in the last quarter. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Price Performance

TYRA stock opened at $31.88 on Monday. Tyra Biosciences, Inc. has a one year low of $9.96 and a one year high of $40.65. The stock has a market cap of $1.90 billion, a price-to-earnings ratio of -14.62 and a beta of 0.77. The company has a fifty day moving average price of $30.48 and a two-hundred day moving average price of $32.69.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.04). Research analysts anticipate that Tyra Biosciences, Inc. will post -2.68 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on TYRA shares. Guggenheim initiated coverage on Tyra Biosciences in a research report on Tuesday, April 14th. They set a "buy" rating and a $54.00 price target on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Tyra Biosciences in a report on Friday, July 17th. Bank of America raised their target price on shares of Tyra Biosciences from $37.00 to $42.00 and gave the company a "buy" rating in a research note on Wednesday, June 10th. Wolfe Research started coverage on shares of Tyra Biosciences in a report on Tuesday, May 19th. They set a "peer perform" rating on the stock. Finally, HC Wainwright reiterated a "buy" rating and issued a $45.00 price target on shares of Tyra Biosciences in a research note on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Tyra Biosciences has a consensus rating of "Moderate Buy" and an average price target of $47.00.

About Tyra Biosciences

Tyra Biosciences NASDAQ: TYRA is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company's pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source